Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy

Natarajan, S.; Subramanian, Poonam

doi:10.1183/13993003.congress-2016.pa2670

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DILI predisposes a patient to develop drug resistant TB. Recurrence of ATT-induced DILI is reported in 10% of cases [3]. Hence, this ATTinduced DILI should be treated promptly.…”

Section: Discussionmentioning

confidence: 96%

Case Series: Antitubercular Therapy-Induced Hepatitis

2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Drug-induced liver injury (DILI) accounts for 20–40% of cases of fulminant hepatic failure. Antitubercular therapy (ATT) may cause hepatotoxicity which can range from transient asymptomatic rise in liver enzymes to acute liver failure. The drugs in ATT responsible for hepatotoxicity include isoniazid, rifampicin, and pyrazinamide. Case series was done to present three different cases of ATT-induced hepatotoxicity which came to the Clinical Pharmacology and Therapeutics Department in NIMS for management.

show abstract

“…DILI predisposes a patient to develop drug resistant TB. Recurrence of ATT-induced DILI is reported in 10% of cases [3]. Hence, this ATTinduced DILI should be treated promptly.…”

Section: Discussionmentioning

confidence: 96%

Case Series: Antitubercular Therapy-Induced Hepatitis

2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy

Cited by 1 publication

References 0 publications

Case Series: Antitubercular Therapy-Induced Hepatitis

Case Series: Antitubercular Therapy-Induced Hepatitis

Contact Info

Product

Resources

About